FDA Needs Better Patient Data to Regulate Stronger Opioids, Experts Say

Drug Industry Daily
A A
The FDA needs more data on the likely impact on patients before it introduces tighter controls on high-strength opioids and doses for outpatient settings, the agency heard in a two-day public meeting.

To View This Article:

Login

Subscribe To Drug Industry Daily